FGF7 and breast cancer: Besides this, the release of FGF7 by CAFs and its interaction with the cognate receptor FGFR2 have been shown to induce ER phosphorylation, ubiquitination, and subsequent proteasomal degradation, therefore counteracting the endocrine treatment in breast cancer cells [83].